• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?

    4/11/24 2:13:17 PM ET
    $ALPN
    $GL
    $KMX
    $NKE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Life Insurance
    Finance
    Get the next $ALPN alert in real time by email

    Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures within the basket.

    Stocks rebounded by noon trading in New York, yet the surge fell short of recovering Wednesday’s losses, indicating lingering nervousness regarding the rate-path outlook.

    Traders have significantly adjusted their expectations for the Fed’s future actions in the past 24 hours, pushing the potential first-rate cut from June to September, with less than two cuts priced in by year-end.

    The tech-heavy Nasdaq 100 outperformed the broader market, up 1.2%, driven by a rally in the semiconductor industry, with Nvidia Corp. (NASDAQ:NVDA) surging 3.1% following a 2% increase the previous day.

    Treasury yields stayed flat in the short-end, while inching higher in the long-end of the curve, triggering further declines in long-dated Treasury bonds. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT) was down 0.2%, on track to the lowest close in nearly six months.

    The U.S. dollar index (DXY) held broadly steady. In Europe, the European Central Bank (ECB) hinted at a potential interest-rate cut in June, pushing back fears of delay linked to U.S. inflation and the Fed’s actions.

    Gold, as tracked by the SPDR Gold Trust (NYSE:GLD), continued to show strong resilience, rising nearly 1% on track to a new record-high close. Bitcoin (CRYPTO: BTC) softened 0.5% to $70,200.

    Wednesday's Performance In US Major Indices, ETFs

    Major IndicesPrice1-day %chg
    Nasdaq 10018,231.111.2%
    Russell 20002,044.590.8%
    S&P 5005,192.430.6%
    Dow Jones38,482.850.0%

    The SPDR S&P 500 ETF Trust (NYSE:SPY) rose 0.7% to $517.50, the SPDR Dow Jones Industrial Average (NYSE:DIA) flat at $384.83 and the tech-heavy Invesco QQQ Trust (NASDAQ:QQQ) rose 1.2% to $443.69, according to Benzinga Pro data. 

    Sector-wise, the Technology Select Sector SPDR Fund (NYSE:XLK) outperformed, up 1.4%, while the Energy Select Sector SPDR Fund (NYSE:XLRE) fell the most, down by 0.4%.

    Thursday’s Stock Movers

    • Nike Inc. (NYSE:NKE) rose 3.8% after Bank of America upgraded the retail giant from Neutral to Buy and raised the price target from $110 to $113.
    • Paramount Global (NASDAQ:PARA) rallied 6.5%, marking the strongest daily performance within the S&P 500, after rumors of the company mulling the sale of VidCon.
    • Globe Life Inc. (NYSE:GL) plummeted by over 35% following allegations of insurance fraud and pyramid scheme behaviors made by short-seller Fuzzy Panda.
    • CarMax Inc. (NYSE:KMX) tumbled 11% after missing earning estimates last quarter.
    • Nikola Corp. (NASDAQ:NKLA) fell nearly 20% after the company’s proposal for a reverse stock split.
    • Alpine Immune Sciences Inc. (NASDAQ:ALPN) skyrocketed 37% after Vertex Pharmaceuticals (NASDAQ:VRTX) announced a $4.9 billion deal to buy Alpine Immune Sciences for $65 per share, implying a 38% premium from Wednesday’s close.

    Read now: Andy Jassy Says Amazon Has Its Hand In Every Layer Of The Generative AI Stack: ‘This Is Going To Transform Virtually Every Experience’

    Image generated using artificial intelligence via Midjourney.

    Get the next $ALPN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPN
    $GL
    $KMX
    $NKE

    CompanyDatePrice TargetRatingAnalyst
    Vertex Pharmaceuticals Incorporated
    $VRTX
    2/13/2026$540.00Perform → Outperform
    Oppenheimer
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/28/2026$606.00Overweight
    Barclays
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/22/2026$546.00Sector Perform → Outperform
    RBC Capital Mkts
    NVIDIA Corporation
    $NVDA
    1/15/2026$240.00Outperform
    RBC Capital Mkts
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/12/2026Mkt Perform → Outperform
    Bernstein
    Nike Inc.
    $NKE
    1/8/2026Hold
    Deutsche Bank
    Nike Inc.
    $NKE
    1/8/2026Buy → Hold
    Needham
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/7/2026$535.00Buy
    UBS
    More analyst ratings

    $ALPN
    $GL
    $KMX
    $NKE
    SEC Filings

    View All

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/18/26 12:28:45 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/18/26 10:46:41 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by NVIDIA Corporation

    13F-HR - NVIDIA CORP (0001045810) (Filer)

    2/17/26 4:27:55 PM ET
    $NVDA
    Semiconductors
    Technology

    $ALPN
    $GL
    $KMX
    $NKE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CO & FO Wagner Charles F Jr was granted 7,365 shares and covered exercise/tax liability with 2,294 shares, increasing direct ownership by 12% to 48,786 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    2/19/26 4:30:13 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Reg. & Quality Off. Tatsis Ourania was granted 5,789 shares, covered exercise/tax liability with 2,294 shares and sold $472,395 worth of shares (977 units at $483.52), increasing direct ownership by 5% to 48,650 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    2/19/26 4:28:26 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP Chief Patient & Ext Af Off Sachdev Amit was granted 5,789 shares and covered exercise/tax liability with 2,140 shares, increasing direct ownership by 6% to 69,042 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    2/19/26 4:24:59 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALPN
    $GL
    $KMX
    $NKE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Meta Builds AI Infrastructure With NVIDIA

    News Summary: Meta expands NVIDIA CPU deployment and significantly improves performance per watt in its data centers.Meta scales out AI workloads with NVIDIA Spectrum-X Ethernet, supporting network efficiency and throughput.Meta has adopted NVIDIA Confidential Computing, enabling AI capabilities while protecting user privacy. SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NVIDIA today announced a multiyear, multigenerational strategic partnership with Meta spanning on-premises, cloud and AI infrastructure. Meta will build hyperscale data centers optimized for both training and inference in support of the company's long-term AI infrastructure roadmap. This partnership will enable

    2/17/26 4:15:00 PM ET
    $NVDA
    Semiconductors
    Technology

    Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions.

    2/17/26 4:00:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Closing the Intent-to-Execution Gap May Define Next Wave of AI Investment

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As artificial intelligence (AI) evolves beyond generative chat systems into agentic AI capable of autonomous action, a critical bottleneck has emerged: the lack of high-fidelity, real-time input connecting human intent to machine execution. While AI models can generate text, images or strategies, translating subtle human signals into actionable machine instructions remains a major technical challenge. Without precise and continuous intent capture, autonomous systems — from humanoid robotics to extended reality (XR) environments — struggle to operate seamlessly alongside humans. Wearable Devices Ltd. (NASDAQ:WLD

    2/17/26 8:30:00 AM ET
    $GOOG
    $NVDA
    $WLDS
    Computer Software: Programming Data Processing
    Technology
    Semiconductors
    Computer Communications Equipment

    $ALPN
    $GL
    $KMX
    $NKE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Blinn Mark A bought $153,540 worth of shares (2,000 units at $76.77) (SEC Form 4)

    4/A - GLOBE LIFE INC. (0000320335) (Issuer)

    2/10/26 7:09:12 PM ET
    $GL
    Life Insurance
    Finance

    PRESIDENT & CEO Hill Elliott bought $1,001,307 worth of Class B Common Stock (16,388 units at $61.10), increasing direct ownership by 7% to 241,587 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/30/25 4:23:10 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Cook Timothy D bought $2,948,500 worth of Class B Common Stock (50,000 units at $58.97), increasing direct ownership by 90% to 105,480 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ALPN
    $GL
    $KMX
    $NKE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vertex Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Vertex Pharma from Perform to Outperform and set a new price target of $540.00

    2/13/26 7:53:31 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Vertex Pharma with a new price target

    Barclays resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $606.00

    1/28/26 7:20:21 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Pharma upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Vertex Pharma from Sector Perform to Outperform and set a new price target of $546.00

    1/22/26 8:24:11 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALPN
    $GL
    $KMX
    $NKE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

    Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

    8/4/23 4:36:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALPN
    $GL
    $KMX
    $NKE
    Leadership Updates

    Live Leadership Updates

    View All

    CarMax Names Keith Barr as Chief Executive Officer

    CarMax, Inc. (NYSE:KMX) ("CarMax" or the "Company") today announced that Keith Barr has been appointed President and Chief Executive Officer, and a member of the Board of Directors ("the Board"), effective March 16, 2026. David McCreight, current Interim President and CEO of CarMax, will transition to his prior duties as an independent Director of the Board. Tom Folliard will remain in his role as Interim Executive Chair of the Board until the Company's Annual Meeting in June 2026, after which he is expected to resume his prior duties as non-executive Chair of the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026021283385

    2/12/26 6:50:00 AM ET
    $IHG
    $KMX
    Hotels/Resorts
    Consumer Discretionary
    Retail-Auto Dealers and Gas Stations

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palantir and NVIDIA Team Up to Operationalize AI — Turning Enterprise Data Into Dynamic Decision Intelligence

    News Summary Palantir is integrating NVIDIA accelerated computing, NVIDIA CUDA-X libraries and open-source NVIDIA Nemotron models into its Ontology framework at the core of the Palantir AI Platform.Lowe's is pioneering operational AI for its supply chain logistics with Palantir and NVIDIA. WASHINGTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- GTC Washington, D.C. -- NVIDIA today announced a collaboration with Palantir Technologies Inc. to build a first-of-its-kind integrated technology stack for operational AI — including analytics capabilities, reference workflows, automation features and customizable, specialized AI agents — to accelerate and optimize complex enterprise and government systems.

    10/28/25 1:36:17 PM ET
    $NVDA
    Semiconductors
    Technology

    $ALPN
    $GL
    $KMX
    $NKE
    Financials

    Live finance-specific insights

    View All

    NIKE, Inc. Declares $0.41 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.41 per share on the Company's outstanding Class A and Class B Common Stock payable on April 1, 2026, to shareholders of record at the close of business on March 2, 2026. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE,

    2/13/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

    — Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue — — Broad mid- and late-stage clinical pipeline accelerates with multiple proof-of-concept and pivotal programs advancing; on track to complete BLA filing for U.S. accelerated approval of povetacicept in IgAN in the first half of 2026 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the f

    2/12/26 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GLOBE LIFE INC. REPORTS FOURTH QUARTER 2025 RESULTS

    MCKINNEY, Texas, Feb. 4, 2026 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) reported today that for the quarter ended December 31, 2025, net income was $3.29 per diluted common share, compared with $3.01 per diluted common share for the year-ago quarter. Net operating income for the quarter was $3.39 per diluted common share, compared with $3.14 per diluted common share for the year-ago quarter. Net income for the year ended December 31, 2025 was $14.07 per diluted common share, compared with $11.94 per diluted common share for the year-ago period. Net operating income for the ye

    2/4/26 4:10:00 PM ET
    $GL
    Life Insurance
    Finance

    $ALPN
    $GL
    $KMX
    $NKE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nikola Corporation

    SC 13G/A - Nikola Corp (0001731289) (Subject)

    11/12/24 5:01:31 PM ET
    $NKLA
    Auto Manufacturing
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NVIDIA Corporation

    SC 13G/A - NVIDIA CORP (0001045810) (Subject)

    11/12/24 10:32:12 AM ET
    $NVDA
    Semiconductors
    Technology

    SEC Form SC 13G filed by Globe Life Inc.

    SC 13G - GLOBE LIFE INC. (0000320335) (Subject)

    11/8/24 10:34:33 AM ET
    $GL
    Life Insurance
    Finance